FT Markets Data
ImmuPharma PLC

Notice of AGM & Annual Report & Accounts

Source: RNS
RNS Number : 2666R
Immupharma PLC
05 June 2024
 

 

 

 

 

RNS: RELEASE                                                                                                                                                   5 June 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM & Annual Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company's Annual General Meeting ("AGM") will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG.

 

The Notice of AGM setting out details of the resolutions, together with the Company's Annual Report and Accounts for the year ended 31 December 2023, has been posted to those shareholders requesting a postal copy; and for other shareholders, these documents will shortly be available to view and download on the Company's website: www.immupharma.co.uk.

 

Ends

For further information please contact:

 

ImmuPharma PLC (www.immupharma.co.uk)

Tim McCarthy, Chairman and Chief Executive Officer

+ 44 (0) 207 206 2650

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 


Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit: www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSLELFBZQLEBBK